Skip to main content

Indaptus Therapeutics, Inc.

INDP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001857044

No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Indaptus Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of INDP: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders619+4
Shares70.6K2385.0K+314.4K (+445.1%)
Value$128.5K$4$1.15M+$1.03M (+798.3%)

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Indaptus Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to INDP in Q2 2026
InstitutionSharesValue% of portfolio
HRT Financial LP206,077$618.0K0.00%
Jane Street Group, LLC53,811$161.4K0.00%
Vanguard Capital Management LLC33,652$101.0K0.00%
Vanguard Fiduciary Trust Co13,967$41.9K0.00%
Millennium Management LLC11,586$34.8K0.00%
UBS Group AG478$1.43K0.00%

Sold out (2)

Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of INDP in Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Citadel Advisors LLC39,018$71.0K
Tower Research Capital LLC (TRC)1,890$3.44K

Not filed for Q2 2026 yet (1)

Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding INDP in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
CWM, LLC2$4